2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2757

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results from a Phase 3 Trial
Abstract Number: 695

Secukinumab Sustains Individual Clinical Responses over Time in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Randomized Placebo-Controlled Trial
Abstract Number: 2251

Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the US Perspective
Abstract Number: 3125

Secular Trend of Premature Mortality in Gout: A Contrast from Rheumatoid Arthritis
Abstract Number: 1719

Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Abstract Number: 2512

Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden
Abstract Number: 3146

Selective Deletion of a Pathogenic Subset Synovial Fibroblasts Attenuates Synovial Inflammation
Abstract Number: 2790

Selective Disruption of Estrogen Receptor Alpha Expression in Dendritic Cells of Lupus-Prone Mice Results in Increased Female-Specific Death
Abstract Number: 462

Selective Inhibition of MMP9 Using a Monoclonal Antibody As a Therapeutic Strategy for Rheumatoid Arthritis
Abstract Number: 1668

Selective Inhibition of Tumor Necrosis Factor-α Receptor 2 (TNFR2) Activity Alleviates Psoriasiform Inflammation in Mouse Models
Abstract Number: 15L

Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis vulgaris and Normalizes Skin Pathology Via Concurrent Regulation of IL-17 and IL-10 Levels
Abstract Number: 1433

Self-Perception Reporting to Healthcare Professionals: Do Individuals with Systemic Sclerosis Report Quality of Life Changes Accurately?
Abstract Number: 2201

Self-Reported Breathlessness on Exertion Is Associated with Poor Outcomes Among Women with Systemic Lupus Erythematosus (SLE)
Abstract Number: 2203

Self-Reported Childhood Maltreatment and Traumatic Events Among Israeli Patients Suffering from Fibromyalgia and Rheumatoid Arthritis
Abstract Number: 2754

Self-Reported Physical Activity Questionnaire in Axial Spondyloarthritis: Modification of the Squash

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].